A Swedish listed biotechnology company

Cantargia is a Swedish biotechnology company that specializes in the development of pharmaceuticals for various types of cancer and inflammatory/autoimmune diseases. Our development programme includes the candidate drugs nadunolimab (CAN04), currently in phase IIa clinical studies, and CAN10, currently in preclinical phase, as well as our discovery project CANxx. The company is listed on OMX Stockholm’s Main List (Small Cap).

Cantargia AB was founded in 2009-2010 with the aim of refining a discovery by Professor Thoas Fioretos and Doctor Marcus Järås of Lund University. Their research showed that leukemic stem cells express a protein on their surface – IL1RAP – that is not expressed to as great a degree on normal stem cells. Further research demonstrated that this protein is also found on cancer cells from a large number of solid tumor types.

We are contributing to cancer treatments of the future

Cancer is a very complex disease, and despite extensive research, there is a considerable need for new treatments. Cancer continues to be one of the most common causes of death, and a disease that is associated with considerable suffering.

At Cantargia, we consider our job not only as important and challenging, but also as an opportunity to contribute to more effective and better tolerated cancer treatments of the future. Our knowledge in the field of cancer research can also be applied to the development of products for other severe conditions, such as inflammatory and autoimmune diseases.

Vision

Cantargia’s vision is to develop a new generation of antibody-based treatments aimed at IL1RAP, with the potential to become an important part of future treatments for life-threatening diseases with better efficacy and safety.